 WALTHAM, Mass.--BUSINESS WIRE--Deciphera Pharmaceuticals, Inc. NASDAQ: DCPH, a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the Swiss Agency for Therapeutic Products Swissmedic has granted approval for QINLOCK ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumor GIST who have received prior treatment with three or more kinase inhibitors, including imati 